Sana Biotechnology Inc. (SANA)
| Bid | 2.17 |
| Market Cap | 484.93M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -252.05M |
| EPS (ttm) | -1.16 |
| PE Ratio (ttm) | -1.86 |
| Forward PE | -3.45 |
| Analyst | Buy |
| Ask | 2.19 |
| Volume | 2,759,681 |
| Avg. Volume (20D) | 7,590,801 |
| Open | 2.39 |
| Previous Close | 2.42 |
| Day's Range | 2.14 - 2.40 |
| 52-Week Range | 1.52 - 10.50 |
| Beta | 1.64 |
About SANA
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin ...
Analyst Forecast
According to 6 analyst ratings, the average rating for SANA stock is "Buy." The 12-month stock price forecast is $9, which is an increase of 317.63% from the latest price.
Stock Forecasts
13 hours ago · seekingalpha.com
Sana Biotechnology: High-Risk High-Reward With Breakthrough UP421SANA develops engineered cell therapies for diabetes, autoimmune diseases, and cancer using ex vivo HIP and in vivo fusogen platforms. SC291 is their CD19‑targeted allogeneic CAR-T candidate which als...
